GTx, Inc.
(NASDAQ : GTXI)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-0.19%104.961.1%$1269.00m
GILDGilead Sciences, Inc.
0.11%72.900.9%$642.29m
AMGNAmgen Inc.
0.18%170.271.1%$478.82m
REGNRegeneron Pharmaceuticals, Inc.
0.69%390.202.7%$361.56m
BIIBBiogen Inc.
-0.38%308.611.2%$348.46m
ALXNAlexion Pharmaceuticals, Inc.
0.69%108.341.9%$268.48m
VRTXVertex Pharmaceuticals Incorporated
-0.25%146.681.9%$232.15m
ALNYAlnylam Pharmaceuticals, Inc
1.09%133.7710.0%$195.26m
INCYIncyte Corporation
-0.29%98.712.5%$178.72m
NKTRNektar Therapeutics
-1.69%48.916.1%$173.60m
ILMNIllumina, Inc.
-0.12%215.103.5%$154.34m
JUNOJuno Therapeutics, Inc.
2.01%61.5413.5%$140.39m
AAgilent Technologies, Inc.
0.48%69.021.5%$132.29m
SRPTSarepta Therapeutics, Inc.
0.22%56.3416.8%$115.87m
BLUEBluebird Bio, Inc.
0.99%168.8517.2%$115.55m

Company Profile

GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN.